ReviewRecipient and donor cells in the graft-versus-solid tumor effect: It takes two to tango
Introduction
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is recognized as one of the most effective strategies in the treatment of advanced hematological cancers, particularly in combination with donor leukocyte infusion (DLI) [[1], [2], [3], [4]]. Whereas treatment with hematopoietic stem cell transplantation was initially conceived to reconstitute the hematopoietic system after high-dose chemo-radiotherapy, soon it became evident that the curative potential of alloHSCT can be attributed to an immune-based response of the transplanted and reconstituting donor cells against the malignant cells, also referred to graft-versus-tumor (GvT) effect [5,6]. Over the last decade, the field of alloHSCT has continued to evolve, with an emerging role for alloHSCT in the treatment of advanced solid tumors [7], and growing evidence on the potential contribution of recipient immune cells in the anti-tumor reactivity following alloHSCT.
Section snippets
AlloHSCT and the existence of a graft-versus-tumor effect
In early alloHSCT regimens, myeloablative conditioning including high-dose chemo-radiotherapy was used to maximally eradicate cancer cells to suppress the recipient immune system and allow donor engraftment. However, such high-dose regimens were associated with high treatment-related toxicities [8] and induction of chemo-resistance [9] while disease recurrence still occurred indicating that high-dose cytotoxic therapy was unable to eliminate tumor cells completely [10]. Moreover, the notion of
AlloHSCT in the treatment of advanced solid tumors
With currently available therapies, several types of advanced-stage solid tumors still present with a bleak prognosis. The observation that GvL effects can produce durable remissions in hematologic cancer patients, led researchers to investigate whether alloHSCT holds potential for solid tumors. Since inflammation was shown to facilitate trafficking of alloreactive T cells from the lymphohematopoietic system into epithelial target cells [24,25], it was postulated that the same mechanism would
A role for recipient immune cells in the anti-tumor effects of alloHSCT
The very first to speculate on a role for recipient immune cells in the anti-tumor effect of donor cell therapy were Alexander et al. in 1966, in a study showing that xenogeneic lymphocytes from tumor-immunized sheep reduced fibrosarcoma growth in immunocompetent rats. The authors postulated that the observed anti-tumor effect was not mediated via direct anti-tumor reactivity of donor T cells as these were rapidly rejected in the xenogeneic setting, but indirectly through what they called a
Conclusion
The finding that alloHSCT can generate immune anti-tumor effects against hematologic as well as solid tumors, is one of the most important advances in the field of HSCT. Although donor T cells are considered the principal mediators of the anti-tumor effect following alloHSCT, recent observations also indicate a key role for recipient-derived immune cells. The presence of recipient APC was shown to be crucial for effective anti-tumor responses as a means to increase the immunocompetence and to
Practice points
- •
There is growing preclinical and clinical evidence to indicate that alloHSCT can provide an immune anti-solid tumor effect.
- •
Clinical observations indicate that full donor chimerism and GvHD are not prerequisites for effective anti-solid tumor immunity after alloHSCT.
- •
Whereas the importance of pre-existing recipient chimerism is well known in anti-tumor responses provided by post-transplant DLI, evidence has emerged indicating that recipient immune cells can also contribute as effectors to the
Research agenda
- •
Prospective monitoring of recipient immune cell activation in clinical trials with alloHSCT for advanced solid tumors would contribute to a better understanding of the emerging role of recipient effector cells in the anti-tumor effect.
- •
Experimental studies should further unravel the interactions between the different effector immune cells thought to be involved in the anti-solid tumor effect of alloHSCT. Experimental models should be expanded to include other common and difficult-to-treat solid
Conflict of interest statement
The authors declare that they have no conflict of interest.
Funding
Isabelle Dierckx de Casterlé is supported by the Olivia Hendrickx Research Fund (www.Olivia.be). This funding source supported the work to obtain the documented findings on the role of recipient effector cells following post-transplant challenge with RLI in the preclinical neuroblastoma model, but had no involvement in the collection, analysis or interpretation of the data, nor in the writing of the manuscript.
References (82)
- et al.
Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions
Biol Blood Marrow Transplant
(2006) - et al.
Donor lymphocyte infusions for relapse after allogeneic transplantation. When, if and for whom?
Blood Rev
(2013) - et al.
Novel therapeutic options in Acute Myeloid Leukemia
Leuk Res Rep
(2016) - et al.
O`utcomes of allogeneic hematopoietic stem cell transplantation for lymphomas: a single-institution experience
Rev Bras Hematol Hemoter
(2016) - et al.
Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients
Blood
(1995) - et al.
Graft-versus-leukemia reactions after bone marrow transplantation
Blood
(1990) - et al.
T-cell depletion of HLA-identical transplants in leukemia
Blood
(1991) - et al.
Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
Blood
(1998) - et al.
Low-dose Total body irradiation and Fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trial
Biol Blood Marrow Transplant
(2010) - et al.
Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial
Biol Blood Marrow Transplant
(2013)
Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioning
Transfus Apher Sci
Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality
Blood
Kinetics of engraftment following allogeneic hematopoietic cell transplantation with reduced-intensity or nonmyeloablative conditioning
Blood Rev
Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study
Blood
The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation
Blood
Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose
Blood
Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease
Blood
Crucial role of timing of donor lymphocyte infusion in generating dissociated graft-versus-host and graft-versus-leukemia responses in mice receiving allogeneic bone marrow transplants
Blood
Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer
Blood
Nonmyeloablative allogeneic hematopoietic stem cell transplantation for metastatic breast cancer
Clin Breast Cancer
Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer
Blood
Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors
Blood
Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe
Ann Oncol
Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors
Blood
Reduced-intensity allogeneic hematopoietic stem cell transplantation in metastatic colorectal cancer as a novel adoptive cell therapy approach. The European group for blood and marrow transplantation experience
Biol Blood Marrow Transplant
Long-term follow-up of allogeneic hematopoietic stem cell transplantation for solid cancer
Biol Blood Marrow Transplant
Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma
Biol Blood Marrow Transplant
Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas
Biol Blood Marrow Transplant
The effect of lymphoid cells from the lymph of specifically immunised sheep on the growth of primary sarcomata in rats
Lancet
The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells
Biol Blood Marrow Transplant
Attempted adoptive immunotherapy of acute leukaemia by leucocyte transfusions
Lancet
A pilot study of allogeneic cellular therapy for patients with advanced hematologic malignancies
Leuk Res
Nonengraftment Haploidentical cellular immunotherapy for refractory malignancies: tumor responses without chimerism
Biol Blood Marrow Transplant
Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients
Blood
Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras
Blood
Mixed chimerism and transplant tolerance
Immunity
Immune tolerance and transplantation
Semin Oncol
Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells
Blood
Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide
Biol Blood Marrow Transplant
Antitumor effect of donor marrow graft rejection induced by recipient leukocyte infusions in mixed chimeras prepared with nonmyeloablative conditioning: critical role for recipient-derived IFN-gamma
Blood
Role of indirect Allo- and autoreactivity in anti-tumor responses induced by recipient leukocyte infusions (RLI) in mixed chimeras prepared with nonmyeloablative conditioning
Clin Immunol
Cited by (8)
Variable impact of graft CD3<sup>+</sup> cell content on graft versus host disease in hematopoietic stem cell transplant recipients: Is the role of donor CD3<sup>+</sup> cells overestimated?
2022, Transfusion and Apheresis ScienceCitation Excerpt :Although donor T cells remain the principal mediators of anti-tumor effect in transplant recipients, the presence of host-derived immune cells is crucial for the progress of the alloreactive responses. Studies showed that relative numbers of donor and host T cells may be more prominent than absolute donor T cell dose in the kinetics of engraftment and aGvHD [27,36–38]. This mutual interplay between donor and recipient cells, which requires a multidirectional and well-rounded evaluation, may help to comprehend the contradictory results of the present study.
Sustained remission after cord blood transplantation for breast cancer with lung metastases and myelodysplastic syndrome
2024, International Journal of HematologyGraft-Versus-Host Disease
2020, Liver Immunology: Principles and PracticeAllogeneic hematopoietic stem cell transplantation for alveolar rhabdomyosarcoma: The first clinical experience of haploidentical transplantation
2020, Pediatric Hematology/Oncology and ImmunopathologyGraft-versus-cancereffect and innovative approaches in the treatment of refractory solid tumors
2020, Turkish Journal of Medical SciencesGraft-Versus-Tumor Effect in Major Histocompatibility Complex–Mismatched Mouse Liver Transplantation
2019, Liver Transplantation
- 1
Shared last authorship